Published in Blood Weekly, May 29th, 2003
Hematologists at the Birmingham Heartlands Hospital, U.K., "studied the outcome of 24 peripheral blood stem cell (PBSC) graft recipients, who were T-cell depleted (TCD) with either 20 mg (n=14) or 10 mg (n=10) Campath-1H in vitro." This group was compared "with a retrospective cohort of 23 unmanipulated (UM) PBSC recipients."
Among the researchers' findings:
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.